Therapy Detail

Therapy Name Octreotide acetate + Cixutumumab + Everolimus
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cixutumumab IMC-A12 IGF1R Antibody 8 Cixutumumab is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (NCI Drug Dictionary).
Everolimus Afinitor RAD001|Zortress mTORC1 Inhibitor 8 Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (
Octreotide acetate Sandostatin Lar Depot SMS 201-995 Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, inhibiting growth hormone, glucagon, and insulin, decreasing LH response to gonadotropin-releasing hormone, decreasing splanchnic blood flow, and inhibiting the release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown neuroendocrine tumor not applicable Octreotide acetate + Cixutumumab + Everolimus Phase I Actionable In a Phase I trial, patients with neuroendocrine tumors treated with the combination of Cixutumumab, Sandostatin Lar Depot (octreotide acetate), and Afinitor (everolimus) demonstrated some efficacy, however, the drug combination did result in multiple non-dose limiting toxicities preventing long term tolerance (PMID: 25900182). 25900182
Clinical Trial Phase Therapies Title Recruitment Status